China's population drops for a fourth straight year

China's population fell for a fourth consecutive year to 1.405 billion in 2025, a decline of 3.39 million from 2024, as births fell to 7.92 million (5.63 per 1,000) from 9.54 million (6.77 per 1,000) and deaths rose to 11.31 million (8.04 per 1,000), producing a negative growth rate of -2.41 per 1,000. The population is aging rapidly: more than 323.38 million people (23%) are over 60 and nearly 16% are over 65, up from 22% and 15.6% a year earlier, a trend that has material implications for long-term labor supply, consumption patterns and healthcare and fiscal demand for investors assessing China exposure.

Analysis

Market structure: The 2025 drop (population 1.405bn, down 3.39m; births 7.92m) accelerates structural demand decline for housing, baby-focused consumer goods and education while boosting per-capita healthcare and eldercare spending — 23% of population now >60. Winners: medical device exporters and operators of senior-care services; losers: residential developers, building materials and low-margin FMCG aimed at young families. Expect multi-year reallocation of capex away from residential construction into health services and automation.

Risk assessment: Near-term (days–weeks) we’ll see risk-off flows into USD and safe-haven bonds; short-term (3–12 months) credit stress for highly leveraged property names; long-term (2–10 years) GDP drag of 0.5–1% p.a. vs prior forecasts if fertility doesn’t recover. Tail risks include a sharp policy U‑turn (large pro-natal subsidies or relaxed household registration), major data revision, or contagion from shadow banking defaults tied to real estate. Hidden dependency: local-government land-sale revenue funds social services — pressure there cascades into fiscal transfers and bank NPLs.

Trade implications: Rotate from China consumer/property beta into healthcare/medtech exporters and senior‑housing REITs; expect commodity demand (iron ore, copper) to undershoot consensus by 5–10% over 12 months. FX: bias to USD/CNH appreciation; Chinese rates likely to moderate but limited by capital controls. Use short-dated options to hedge China equity exposure and take medium-term directional positions in selective names with China growth exposure.

Contrarian angles: Consensus will overweight macro call to ‘China reopening growth,’ but that misses demography-driven secular demand shifts — the mispricing is sectoral not countrywide. Healthcare and eldercare chains in China (and global exporters with >10% China revenue) are under-owned and may rerate if policy shifts to eldercare subsidies. Conversely, some large SOE developers may be artificially depressed and offer selective long risk/reward if state support materializes.

Key Decisions for Investors

• Establish 2–3% long positions each in Medtronic (MDT) and Stryker (SYK) to capture China medtech share gains; target +20% upside over 12–24 months, stop-loss 10%.
• Reduce China consumer/internet exposure: trim KWEB and MCHI weights by 40% vs current benchmark within 5 trading days and redeploy proceeds into healthcare and global medtech names.
• Initiate hedges: buy 3–6 month KWEB or FXI puts ~15% OTM sized 0.5–1% of portfolio notional to protect China beta while assessing policy response.
• Short selective Chinese property risk: establish a small (0.5–1% notional) short position in high‑beta HK-listed developers (eg, 3333.HK Evergrande exposure via CDS or short equity if available) with a 6–12 month horizon; take profits or cover if clear state backstop announced.
• Position for RMB weakness: increase USD cash by 3–5% and enter a 6–12 month USD/CNH long NDF or appropriate FX option targeting 3–6% RMB depreciation (exit if RMB moves >6% from current level).